Abstract Library

#4625 Efficacy and safety of capecitabine-temozolomide (CAPTEM) regimen in patients with neuroendocrine neoplasms – A systematic review and experience from NETwerk, a Belgian ENETS Center of Excellence

Introduction: Current treatment guidelines remain inconclusive due to scarcity of data regarding the optimal systemic treatment for metastatic gastroenteropancreatic (GEP) neuroendocrine tumours (NET) grade 3 and aggressive GEP-NET grade 2. Similarly, for metastatic pulmonary typical (TC) and atypical carcinoids (AC), the indication for chemotherapy is unclear. Recent evidence highlights a promising role for CAPTEM, combining temozolomide (TEM) with capecitabine (CAP), showing encouraging antitumoural activity and safety profiles for these indications.

Conference:

Presenting Author: Chhajlani S

Authors: Chhajlani S, Lambrechts C, Islam O, de Weerdt C, Verbruggen L,

Keywords: capecitabine, temozolomide, CAPTEM, GEP-NET, pulmonary NEN, safety, efficacy, systematic review,

#3634 Imaging surveillance in multiple endocrine neoplasia type 1 – 10 years of experience with somatostatin receptor positron emission tomography

Introduction: Guidelines for multiple endocrine neoplasia type 1 (MEN1) recommend intensive imaging surveillance without specifying a superior regimen, including the role of somatostatin receptor imaging (SRI) with positron emission tomography (PET).

Conference:

Presenting Author: Andreassen M

Authors: Said M, Krogh J, Feldt-Rasmussen U, Rasmussen �, Kristensen T,

Keywords: Imaging, Multiple endocrine neoplasia type 1, Neuroendocrine neoplasm, Positron emission tomography, Somatostatin receptor,

#3461 Gender specific differences in overall survival (OS) in patients with pulmonary neuroendocrine neoplasms (NENs) in a large United Kingdom (UK) tertiary centre

Introduction: Pulmonary NENs account for approximately 2% of all pulmonary malignancy. Overall survival data is mainly based on the USA SEER database or surgical cohorts, but data for the UK population is lacking. Only a few studies report on gender related outcomes and demonstrate no sex differences in overall survival.

Conference:

Presenting Author: Clement D

Authors: Clement D, Richardson D, Brown S, Mulholland N, Sarker D,

Keywords: typical carcinoid, atypical carcinoid, survival, gender difference, pulmonary neuroendocrine carcinoma,

#3158 Incidence of brain metastases (BMs) and outcomes in patients (pts) with extrapulmonary neuroendocrine neoplasms (EP-NENs)

Introduction: The incidence, management and outcomes of pts with EP-NENs and BMs are unclear.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Kapacee Z, Dawod M, Allison J, Frizziero M, Chakrabarty B,

Keywords: brain metastases, extrapulmonary NENs, radiotherapy, whole brain radiotherapy, survival, grade 3 NEC,

#3072 Rb and p53 Status Determination by Immunochemistry Is Complementary in Routine Practice to Genetic Testing of Neuroendocrine Neoplasms

Introduction: Rb and p53 status may help distinguishing well from poorly differentiated neuroendocrine neoplasms (NEN) and may predict response to chemotherapy. Studies correlating Rb/p53 genetic and immunohistochemistry were performed on high-quality frozen samples with high throughput techniques efficient for copy number determination. This situation differs from routine practice in which small deletions may be hard to detect on formalin-fixed paraffin-embedded (FFPE) samples with a gene panel approach.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Cros J

Authors: Chen R, Lacroix L, De Rycke O, Lacombe C, Cazes A,

Keywords: rb, p53, aggressive neuroendocrine tumors, biomarker,